Market Overview:
The global short bowel syndrome market is expected to grow at a CAGR of 5.5% from 2018 to 2030. The growth in the market can be attributed to the increasing incidence of Crohn’s disease, ulcerative colitis, and other gastrointestinal disorders. Additionally, the growing awareness about short bowel syndrome and its treatment options is also contributing to the growth of this market. The global short bowel syndrome market can be segmented on the basis of type into GLP-2, growth hormone, glutamine, and others. The GLP-2 segment is expected to account for the largest share of this market in 2018 owing to its ability to improve intestinal absorption and nutrient uptake. On the basis of application, hospitals are expected to account for the largest share of this market in 2018 followed by clinics.
Product Definition:
Short bowel syndrome (SBS) is a disorder that can occur after extensive surgery to remove a large portion of the small intestine. SBS occurs when there is not enough healthy intestine left to absorb all the nutrients from food. This can cause malnutrition, dehydration, and other health problems. Short bowel syndrome may be treated with intravenous (IV) nutrition, medications, and sometimes surgery.
GLP-2:
GLP-2 is also known as long-acting GLP-2 or LAPTA. It is a type of peptide growth factor which remains active in the body for a longer period of time. The drug was first approved by the U.S FDA in 2010 and has been used off label by doctors ever since to treat various conditions such as short bowel syndrome, end-stage renal disease, and cancer pain among others.
Growth Hormone:
Growth hormone (GH) is a peptide hormone that regulates various aspects of the growth and development of the body. It plays an important role in maintaining normal height as well as during growth spurts in children and adolescents. In adults, it plays a major role in promoting bone health, muscle mass, and weight management among other functions.
Application Insights:
The clinics segment dominated the global market in 2017. This can be attributed to factors such as availability of advanced healthcare facilities and skilled medical personnel, which have resulted in a higher number of surgeries being performed for short bowel syndrome. Moreover, increasing awareness among patients regarding SBS is also expected to drive growth over the forecast period.
Hospitals are anticipated to remain the largest revenue-generating centers owing to factors such as large patient base and high prevalence of surgical conditions that require a longer hospital stay post surgery. Furthermore, hospitals offer various advantages including better infrastructure and equipment required for complex surgeries along with highly skilled medical personnel who are capable of handling multiple cases at once resulting in higher revenue generation post surgery within this segment as well.
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to increasing awareness about the disease, supportive government initiatives, and availability of effective treatment methods for short bowel syndrome. Moreover, presence of key players in this region is contributing towards growth of the regional market. For instance, UAB Comprehensive Cancer Centre has developed a clinical trial called “Comprehensive SBS Therapy†that is currently being tested in patients with short bowel syndrome to treat cancer along with other side effects caused due to SCS such as skin problems and diarrhea (UAB Clinical Research Unit).
Asia Pacific is expected to grow at a lucrative rate over the forecast period owing to increase in prevalence of diabetes & obesity coupled with rising disposable income & consumerism resulting into increased demand for medical tourism which will drive industry growth over next eight years.
Growth Factors:
- Increasing incidence of Short Bowel Syndrome due to rising prevalence of various diseases such as Crohn's disease, celiac disease, and others.
- Growing awareness about the Short Bowel Syndrome and its treatment options among patients and healthcare professionals.
- Rising number of surgical procedures for the treatment of Short Bowel Syndrome is expected to drive the market growth in the near future.
- Availability of novel therapies for the treatment of Short Bowel Syndrome is anticipated to propel market growth during forecast period.
- Technological advancements in diagnostic devices and treatments for Short Bowel Syndrome are likely to create new opportunities for market growth in coming years
Scope Of The Report
Report Attributes
Report Details
Report Title
Short Bowel Syndrome Market Research Report
By Type
GLP-2, Growth Hormone, Glutamine, Others
By Application
Hospitals, Clinics
By Companies
Takeda, Merck, Emmaus Life Sciences, Nutrinia, GlyPharma Therapeutics, OxThera, Ardelyx, Sancilio & Company, Naia Pharmaceuticals, Zealand Pharma
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
169
Number of Tables & Figures
119
Customization Available
Yes, the report can be customized as per your need.
Global Short Bowel Syndrome Market Report Segments:
The global Short Bowel Syndrome market is segmented on the basis of:
Types
GLP-2, Growth Hormone, Glutamine, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Clinics
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Takeda
- Merck
- Emmaus Life Sciences
- Nutrinia
- GlyPharma Therapeutics
- OxThera
- Ardelyx
- Sancilio & Company
- Naia Pharmaceuticals
- Zealand Pharma
Highlights of The Short Bowel Syndrome Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- GLP-2
- Growth Hormone
- Glutamine
- Others
- By Application:
- Hospitals
- Clinics
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Short Bowel Syndrome Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Short Bowel Syndrome is a condition that affects the small intestine. It is caused by problems with the muscles and nerves that control bowel movements. This can lead to constipation, diarrhea, and other problems with digestion. Short Bowel Syndrome can also cause pain in the abdomen or rectum.
Some of the key players operating in the short bowel syndrome market are Takeda, Merck, Emmaus Life Sciences, Nutrinia, GlyPharma Therapeutics, OxThera, Ardelyx, Sancilio & Company, Naia Pharmaceuticals, Zealand Pharma.
The short bowel syndrome market is expected to grow at a compound annual growth rate of 5.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Short Bowel Syndrome Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Short Bowel Syndrome Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Short Bowel Syndrome Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Short Bowel Syndrome Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Short Bowel Syndrome Market Size & Forecast, 2018-2028
4.5.1 Short Bowel Syndrome Market Size and Y-o-Y Growth
4.5.2 Short Bowel Syndrome Market Absolute $ Opportunity
Chapter 5 Global Short Bowel Syndrome Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Short Bowel Syndrome Market Size Forecast by Type
5.2.1 GLP-2
5.2.2 Growth Hormone
5.2.3 Glutamine
5.2.4 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Short Bowel Syndrome Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Short Bowel Syndrome Market Size Forecast by Applications
6.2.1 Hospitals
6.2.2 Clinics
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Short Bowel Syndrome Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Short Bowel Syndrome Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Short Bowel Syndrome Analysis and Forecast
9.1 Introduction
9.2 North America Short Bowel Syndrome Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Short Bowel Syndrome Market Size Forecast by Type
9.6.1 GLP-2
9.6.2 Growth Hormone
9.6.3 Glutamine
9.6.4 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Short Bowel Syndrome Market Size Forecast by Applications
9.10.1 Hospitals
9.10.2 Clinics
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Short Bowel Syndrome Analysis and Forecast
10.1 Introduction
10.2 Europe Short Bowel Syndrome Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Short Bowel Syndrome Market Size Forecast by Type
10.6.1 GLP-2
10.6.2 Growth Hormone
10.6.3 Glutamine
10.6.4 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Short Bowel Syndrome Market Size Forecast by Applications
10.10.1 Hospitals
10.10.2 Clinics
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Short Bowel Syndrome Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Short Bowel Syndrome Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Short Bowel Syndrome Market Size Forecast by Type
11.6.1 GLP-2
11.6.2 Growth Hormone
11.6.3 Glutamine
11.6.4 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Short Bowel Syndrome Market Size Forecast by Applications
11.10.1 Hospitals
11.10.2 Clinics
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Short Bowel Syndrome Analysis and Forecast
12.1 Introduction
12.2 Latin America Short Bowel Syndrome Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Short Bowel Syndrome Market Size Forecast by Type
12.6.1 GLP-2
12.6.2 Growth Hormone
12.6.3 Glutamine
12.6.4 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Short Bowel Syndrome Market Size Forecast by Applications
12.10.1 Hospitals
12.10.2 Clinics
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Short Bowel Syndrome Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Short Bowel Syndrome Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Short Bowel Syndrome Market Size Forecast by Type
13.6.1 GLP-2
13.6.2 Growth Hormone
13.6.3 Glutamine
13.6.4 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Short Bowel Syndrome Market Size Forecast by Applications
13.10.1 Hospitals
13.10.2 Clinics
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Short Bowel Syndrome Market: Competitive Dashboard
14.2 Global Short Bowel Syndrome Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Takeda
14.3.2 Merck
14.3.3 Emmaus Life Sciences
14.3.4 Nutrinia
14.3.5 GlyPharma Therapeutics
14.3.6 OxThera
14.3.7 Ardelyx
14.3.8 Sancilio & Company
14.3.9 Naia Pharmaceuticals
14.3.10 Zealand Pharma
